IL-17A Levels in the Sera of Patients with Gastric Cancer Show Limited Elevation

  • Malek-Hosseini, Zahra (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences) ;
  • Taherinejad, Marziye (Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences) ;
  • Malekzadeh, Mahyar (Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences) ;
  • Ghaderi, Abbas (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences) ;
  • Doroudchi, Mehrnoosh (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences)
  • Published : 2015.11.04


Background: Inflammation plays a major role in the development and progression of gastric and other gastrointestinal tumors. The IL-17 family of cytokines has been under investigation as targets of immunotherapy. Materials and Methods: We investigated the levels of IL-17A inflammatory cytokine in the sera of 57 patients with gastric cancer (GC) and 90 healthy age/sex matched controls using ELISA methods. Results: In only 5 (8.8%) of the patients' sera was IL-17A detectable. No IL-17A was apparent in the sera of healthy controls. The maximum concentration of IL-17A in patients was 7.004 pg/ml. Vascular and lymphatic invasions were only seen in one of the 5 positive cases. Although all of them were in the age group >60 years, no correlation was seen between age and IL-17A level. These results are somewhat different from our findings for colorectal cancer (CRC) in the same population. Conclusions: It is possible that the inflammopathology of CRC and GC are rather different, at least in Fars, a southern province of Iran.


  1. Benchetrit F, Ciree A, Vives V, et al (2002). Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood, 99, 2114-21.
  2. Cancer incidence in five continents (2002). Volume VIII. IARC Sci Publ, 1-781.
  3. Caruso R, Pallone F, Monteleone G (2007). Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol, 13, 5547-51.
  4. Coupland VH, Lagergren J, Konfortion J, et al (2012). Ethnicity in relation to incidence of oesophageal and gastric cancer in England. Br J Cancer, 107, 1908-14.
  5. Doroudchi M, Pishe ZG, Malekzadeh M, et al (2013a). Elevated serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac J Cancer Prev, 14, 5225-30.
  6. Doroudchi M, Saidi M, Malekzadeh M, et al (2013b). Elevated IL-17A levels in early stages of bladder cancer regardless of smoking status. Future Oncol, 9, 295-304.
  7. Eshraghian A (2014). Epidemiology of Helicobacter pylori infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: a systematic review of prevalence and risk factors. World J Gastroenterol, 20, 17618-25.
  8. Ghasemi-Kebria F, Ghaemi E, Azadfar S, et al (2013). Epidemiology of Helicobacter pylori infection among Iranian children. Arab J Gastroenterol, 14, 4.
  9. Hassanzade J, Molavi e vardanjan iH, Farahmand M, et al (2011). Incidence and mortality rate of common gastrointestinal cancers in south of iran, a population based study. Iran J Cancer Prev, 4, 7.
  10. He S, Fei M, Wu Y, et al (2011). Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci, 12, 7424-37.
  11. Jafarzadeh A, Mirzaee V, Ahmad-Beygi H, et al (2009). Association of the CagA status of Helicobacter pylori and serum levels of interleukin (IL)-17 and IL-23 in duodenal ulcer patients. J Dig Dis, 10, 107-12.
  12. Jin W, Dong C (2013). IL-17 cytokines in immunity and inflammation. Emerging Microbes and Infections, 2, 1-5.
  13. Kryczek I, Wei S, Szeliga W, et al (2009). Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood, 114, 357-9.
  14. Landskron G, De la Fuente M, Thuwajit P, et al (2014). Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res, 2014, 149185.
  15. Layke JC, Lopez PP (2004). Gastric cancer: diagnosis and treatment options. Am Fam Physician, 69, 1133-40.
  16. Liu C, Zhang Y, Zhan J, et al (2014a). Interleukin-23A is associated with tumor growth in Helicobacter-pylori-related human gastric cancer. Cancer Cell Int, 14, 104.
  17. Liu X, Jin H, Zhang G, et al (2014b). Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients. PLoS One, 9, 106834.
  18. Lv L, Pan K, Li XD, et al (2011). The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One, 6, 18219.
  19. Ma C, Dong X (2011). Colorectal cancer-derived Foxp3(+) IL- 17(+) T cells suppress tumour-specific CD8+ T cells. Scand J Immunol, 74, 47-51.
  20. Ma M, Jin GJ, Yun K, et al (2015). Correlation of IL-1F genetic polymorphisms with the risk of colorectal cancer among Chinese populations. Tumour Biol, 36, 807-14.
  21. Malekzadeh M, Dehaghani AS, Ghaderi A, et al (2013). IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma. Cancer Biomark, 13, 417-25.
  22. Malekzadeh R, Derakhshan MH, Malekzadeh Z (2009). Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med, 12, 576-83.
  23. Matveeva LV, Mosina LM (2013). The changes in serum concentrations of interleukin-17 in diseases gastroduodenal zone. Eksp Klin Gastroenterol, 8, 24-7.
  24. Mehrabani D, Hosseini SV, Rezaianzadeh A, et al (2013). Prevalence of stomach cancer in Shiraz, Southern Iran. J Res Med Sci, 18, 335-7.
  25. Meng XY, Zhou CH, Ma J, et al (2012). Expression of interleukin-17 and its clinical significance in gastric cancer patients. Med Oncol, 29, 3024-8.
  26. Murugaiyan G, Saha B (2009). Protumor vs antitumor functions of IL-17. J Immunol, 183, 4169-75.
  27. Nemati K, Golmoghaddam H, Hosseini SV, et al (2015). Interleukin-17FT7488 allele is associated with a decreased risk of colorectal cancer and tumor progression. Gene, 561, 88-94.
  28. Niknam R, Seddigh M, Fattahi MR, et al (2014). Prevalence of Helicobacter pylori in Patients With Dyspepsia. Jundishapur J Microbiol, 7, 12676.
  29. Numasaki M, Fukushi J, Ono M, et al (2003). Interleukin-17 promotes angiogenesis and tumor growth. Blood, 101, 2620-7.
  30. Oluwasola AO (2014). Genetic determinants and clinicopathological outcomes of Helicobacter pylori infection. Ann Ib Postgrad Med, 12, 22-30.
  31. Omrane I, Marrakchi R, Baroudi O, et al (2014). Significant association between interleukin-17A polymorphism and colorectal cancer. Tumour Biol, 35, 6627-32.
  32. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
  33. Petanidis S, Anestakis D, Argyraki M, et al (2013). Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-gamma. PLoS One, 8, 73616.
  34. Ren Z, Li M, Liu R, et al (2014). Interleukin 17A rs3819024 A>G polymorphism is associated with an increased risk of gastric cardia adenocarcinoma in a Chinese population. Biomarkers, 19, 411-6.
  35. Rokkappanavar K Kumar SSR, Esaki M Shankar, E Ganapathy, Abdul S Ebrahim, Shukkur M Farooq (2013). Gastric Carcinoma- New Insights into Current Management 271-93, edited by Daniela Lazar, ISBN 978-953-51-0914-3, InTech, January 1, 2013
  36. Saito H, Yamada Y, Takaya S, et al (2015). Clinical relevance of the number of interleukin-17-producing CD 8+ T cells in patients with gastric cancer. Surg Today.
  37. Su X, Ye J, Hsueh EC, et al (2010). Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol, 184, 1630-41.
  38. Tesmer LA, Lundy SK, Sarkar S, et al (2008). Th17 cells in human disease. Immunol Rev, 223, 87-113.
  39. Toy D, Kugler D, Wolfson M, et al (2006). Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol, 177, 36-9.
  40. Tsugane S, Sasazuki S (2007). Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer, 10, 75-83.
  41. Wang L, Yi T, Kortylewski M, et al (2009). IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med, 206, 1457-64.
  42. Wang N, Yang J, Lu J, et al (2014). IL-17 gene polymorphism is associated with susceptibility to gastric cancer. Tumour Biol, 35, 10025-30.
  43. Wu D, Wu P, Huang Q, et al (2013). Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol, 2013, 436307.
  44. Yan S, Li B, Bai ZZ, et al (2014). Clinical epidemiology of gastric cancer in Hehuang valley of China: a 10-year epidemiological study of gastric cancer. World J Gastroenterol, 20, 10486-94.
  45. Yu H, Sun S, Liu F, et al (2014). Meta-analysis of associations between interleukin-17 gene polymorphisms and risk of gastric cancer. Asian Pac J Cancer Prev, 15, 8709-13.
  46. Zhang JP, Yan J, Xu J, et al (2009). Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol, 5, 980-9.

Cited by

  1. Interleukins 17 and 23 in patients with gastric neoplasms vol.6, pp.1, 2016,